Janssen targeting innovation way beyond me-too drugs in neuroscience, says Lars Leppin

1 December 2021

The Johnson & Johnson (NYSE: JNJ) unit Janssen has been active in neuroscience since the beginnings of the company, with its first product coming in this space, so each new major breakthrough in the area is a continuation of a rich tradition.

The multiple sclerosis (MS) drug Ponvory (ponesimod) looks to be the latest in the long line of such advances, with recent results from the Phase III OPTIMUM study showing benefits in early MS over teriflunomide, a Sanofi (Euronext: SAN) product sold under the brand name Aubagio.

'Something to make a difference'

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK